These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23374867)

  • 21. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.
    Zhang L; Balan G; Barreiro G; Boscoe BP; Chenard LK; Cianfrogna J; Claffey MM; Chen L; Coffman KJ; Drozda SE; Dunetz JR; Fonseca KR; Galatsis P; Grimwood S; Lazzaro JT; Mancuso JY; Miller EL; Reese MR; Rogers BN; Sakurada I; Skaddan M; Smith DL; Stepan AF; Trapa P; Tuttle JB; Verhoest PR; Walker DP; Wright AS; Zaleska MM; Zasadny K; Shaffer CL
    J Med Chem; 2014 Feb; 57(3):861-77. PubMed ID: 24392688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel series of metabotropic glutamate receptor 5 negative allosteric modulators based on a 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine core.
    Duvey G; Perry B; Le Poul E; Poli S; Bonnet B; Lambeng N; Charvin D; Donovan-Rodrigues T; Haddouk H; Gagliardi S; Rocher JP
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4523-7. PubMed ID: 23850200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators.
    Rodriguez AL; Nong Y; Sekaran NK; Alagille D; Tamagnan GD; Conn PJ
    Mol Pharmacol; 2005 Dec; 68(6):1793-802. PubMed ID: 16155210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative allosteric modulation of metabotropic glutamate receptor 5 attenuates alcohol self-administration in baboons.
    Salling MC; Grassetti A; Ferrera VP; Martinez D; Foltin RW
    Pharmacol Biochem Behav; 2021 Sep; 208():173227. PubMed ID: 34224733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
    Rook JM; Xiang Z; Lv X; Ghoshal A; Dickerson JW; Bridges TM; Johnson KA; Foster DJ; Gregory KJ; Vinson PN; Thompson AD; Byun N; Collier RL; Bubser M; Nedelcovych MT; Gould RW; Stauffer SR; Daniels JS; Niswender CM; Lavreysen H; Mackie C; Conde-Ceide S; Alcazar J; Bartolomé-Nebreda JM; Macdonald GJ; Talpos JC; Steckler T; Jones CK; Lindsley CW; Conn PJ
    Neuron; 2015 May; 86(4):1029-1040. PubMed ID: 25937172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors.
    Harvey BD; Siok CJ; Kiss T; Volfson D; Grimwood S; Shaffer CL; Hajós M
    Neuropharmacology; 2013 Dec; 75():19-30. PubMed ID: 23831682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and optimization of 4,5,6,7-tetrahydrooxazolo[4,5-c]pyridines as potent and orally-active metabotropic glutamate receptor 5 negative allosteric modulators.
    Hirose W; Kato Y; Natsutani I; Takata M; Kitaichi M; Imai S; Hayashi S; Arai Y; Hoshino K; Yoshida K
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4331-4335. PubMed ID: 28838696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators.
    Chae E; Shin YJ; Ryu EJ; Ji MK; Ryune Cho N; Lee KH; Jeong HJ; Kim SJ; Choi Y; Seok Oh K; Park CE; Soo Yoon Y
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2134-9. PubMed ID: 23434029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities.
    Zhu CZ; Wilson SG; Mikusa JP; Wismer CT; Gauvin DM; Lynch JJ; Wade CL; Decker MW; Honore P
    Eur J Pharmacol; 2004 Dec; 506(2):107-18. PubMed ID: 15588730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of 6-(pyrimidin-5-ylmethyl)quinoline-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5.
    Felts AS; Rodriguez AL; Morrison RD; Blobaum AL; Byers FW; Daniels JS; Niswender CM; Conn PJ; Lindsley CW; Emmitte KA
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1679-1685. PubMed ID: 29705142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety.
    Busse CS; Brodkin J; Tattersall D; Anderson JJ; Warren N; Tehrani L; Bristow LJ; Varney MA; Cosford ND
    Neuropsychopharmacology; 2004 Nov; 29(11):1971-9. PubMed ID: 15305166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity.
    Anighoro A; Graziani D; Bettinelli I; Cilia A; De Toma C; Longhi M; Mangiarotti F; Menegon S; Pirona L; Poggesi E; Riva C; Rastelli G
    Bioorg Med Chem; 2015 Jul; 23(13):3040-58. PubMed ID: 26014480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
    Liu F; Grauer S; Kelley C; Navarra R; Graf R; Zhang G; Atkinson PJ; Popiolek M; Wantuch C; Khawaja X; Smith D; Olsen M; Kouranova E; Lai M; Pruthi F; Pulicicchio C; Day M; Gilbert A; Pausch MH; Brandon NJ; Beyer CE; Comery TA; Logue S; Rosenzweig-Lipson S; Marquis KL
    J Pharmacol Exp Ther; 2008 Dec; 327(3):827-39. PubMed ID: 18753411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADX-47273, a mGlu5 receptor positive allosteric modulator, attenuates deficits in cognitive flexibility induced by withdrawal from 'binge-like' ethanol exposure in rats.
    Marszalek-Grabska M; Gibula-Bruzda E; Bodzon-Kulakowska A; Suder P; Gawel K; Talarek S; Listos J; Kedzierska E; Danysz W; Kotlinska JH
    Behav Brain Res; 2018 Feb; 338():9-16. PubMed ID: 29030082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia.
    Conde-Ceide S; Alcázar J; Alonso de Diego SA; López S; Martín-Martín ML; Martínez-Viturro CM; Pena MA; Tong HM; Lavreysen H; Mackie C; Bridges TM; Daniels JS; Niswender CM; Jones CK; Macdonald GJ; Steckler T; Conn PJ; Stauffer SR; Lindsley CW; Bartolomé-Nebreda JM
    Bioorg Med Chem Lett; 2016 Jan; 26(2):429-434. PubMed ID: 26684851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist with anxiolytic activity.
    Roppe JR; Wang B; Huang D; Tehrani L; Kamenecka T; Schweiger EJ; Anderson JJ; Brodkin J; Jiang X; Cramer M; Chung J; Reyes-Manalo G; Munoz B; Cosford ND
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3993-6. PubMed ID: 15225713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DSR-98776, a novel selective mGlu5 receptor negative allosteric modulator with potent antidepressant and antimanic activity.
    Kato T; Takata M; Kitaichi M; Kassai M; Inoue M; Ishikawa C; Hirose W; Yoshida K; Shimizu I
    Eur J Pharmacol; 2015 Jun; 757():11-20. PubMed ID: 25823809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5).
    Martín-Martín ML; Bartolomé-Nebreda JM; Conde-Ceide S; Alonso de Diego SA; López S; Martínez-Viturro CM; Tong HM; Lavreysen H; Macdonald GJ; Steckler T; Mackie C; Bridges TM; Daniels JS; Niswender CM; Noetzel MJ; Jones CK; Conn PJ; Lindsley CW; Stauffer SR
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1310-7. PubMed ID: 25683622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5.
    Bian Y; Feng Z; Yang P; Xie XQ
    AAPS J; 2017 Jul; 19(4):1235-1248. PubMed ID: 28560482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations.
    Fu T; Zheng G; Tu G; Yang F; Chen Y; Yao X; Li X; Xue W; Zhu F
    ACS Chem Neurosci; 2018 Jun; 9(6):1492-1502. PubMed ID: 29522307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.